Published in Cancer Cell on April 01, 2007
Initial genome sequencing and analysis of multiple myeloma. Nature (2011) 17.28
Selective inhibition of tumor oncogenes by disruption of super-enhancers. Cell (2013) 8.37
Structure of the dual enzyme Ire1 reveals the basis for catalysis and regulation in nonconventional RNA splicing. Cell (2008) 4.59
Regulated Ire1-dependent decay of messenger RNAs in mammalian cells. J Cell Biol (2009) 4.51
Endoplasmic reticulum stress in disease pathogenesis. Annu Rev Pathol (2008) 4.10
The genetic architecture of multiple myeloma. Nat Rev Cancer (2012) 3.71
Targeting the unfolded protein response in disease. Nat Rev Drug Discov (2013) 3.37
Prognostic significance of copy-number alterations in multiple myeloma. J Clin Oncol (2009) 3.21
Bortezomib induces canonical nuclear factor-kappaB activation in multiple myeloma cells. Blood (2009) 3.12
XBP1 promotes triple-negative breast cancer by controlling the HIF1α pathway. Nature (2014) 2.84
The critical roles of endoplasmic reticulum chaperones and unfolded protein response in tumorigenesis and anticancer therapies. Oncogene (2012) 2.82
Regulation of basal cellular physiology by the homeostatic unfolded protein response. J Cell Biol (2010) 2.40
Divergent effects of PERK and IRE1 signaling on cell viability. PLoS One (2009) 2.30
Bone marrow microenvironment and the identification of new targets for myeloma therapy. Leukemia (2008) 2.29
Role of endoplasmic reticulum stress in metabolic disease and other disorders. Annu Rev Med (2012) 1.98
Xbp1s-negative tumor B cells and pre-plasmablasts mediate therapeutic proteasome inhibitor resistance in multiple myeloma. Cancer Cell (2013) 1.88
Blockade of XBP1 splicing by inhibition of IRE1α is a promising therapeutic option in multiple myeloma. Blood (2012) 1.81
XBP-1 regulates signal transduction, transcription factors and bone marrow colonization in B cells. EMBO J (2009) 1.72
Structure of the Ire1 autophosphorylation complex and implications for the unfolded protein response. EMBO J (2011) 1.65
Unfolded protein response transcription factor XBP-1 does not influence prion replication or pathogenesis. Proc Natl Acad Sci U S A (2008) 1.60
MHC class I chain-related protein A antibodies and shedding are associated with the progression of multiple myeloma. Proc Natl Acad Sci U S A (2008) 1.59
Potent and selective inhibitors of the inositol-requiring enzyme 1 endoribonuclease. J Biol Chem (2011) 1.58
Divergent allosteric control of the IRE1α endoribonuclease using kinase inhibitors. Nat Chem Biol (2012) 1.46
Unfolded protein response in cancer: the physician's perspective. J Hematol Oncol (2011) 1.45
Stimulation of surface IgM of chronic lymphocytic leukemia cells induces an unfolded protein response dependent on BTK and SYK. Blood (2014) 1.45
Commensal microbiota and CD8+ T cells shape the formation of invariant NKT cells. J Immunol (2010) 1.43
Biologic sequelae of I{kappa}B kinase (IKK) inhibition in multiple myeloma: therapeutic implications. Blood (2009) 1.41
Multiple myeloma cancer stem cells. J Clin Oncol (2008) 1.39
Endoplasmic reticulum stress: its role in disease and novel prospects for therapy. Scientifica (Cairo) (2012) 1.37
Imaging the unfolded protein response in primary tumors reveals microenvironments with metabolic variations that predict tumor growth. Cancer Res (2009) 1.34
Unfolded protein response to autophagy as a promising druggable target for anticancer therapy. Ann N Y Acad Sci (2012) 1.21
Regulation of unfolded protein response modulator XBP1s by acetylation and deacetylation. Biochem J (2011) 1.19
A proto-oncogene BCL6 is up-regulated in the bone marrow microenvironment in multiple myeloma cells. Blood (2010) 1.18
Emerging roles for XBP1, a sUPeR transcription factor. Gene Expr (2010) 1.17
Inhibition of ER stress-associated IRE-1/XBP-1 pathway reduces leukemic cell survival. J Clin Invest (2014) 1.16
Cancer stem cells: controversies in multiple myeloma. J Mol Med (Berl) (2009) 1.15
The mammalian tRNA ligase complex mediates splicing of XBP1 mRNA and controls antibody secretion in plasma cells. EMBO J (2014) 1.15
Role of CAAT/enhancer binding protein homologous protein in panobinostat-mediated potentiation of bortezomib-induced lethal endoplasmic reticulum stress in mantle cell lymphoma cells. Clin Cancer Res (2010) 1.14
Translational infidelity-induced protein stress results from a deficiency in Trm9-catalyzed tRNA modifications. RNA Biol (2012) 1.13
Dual function of pancreatic endoplasmic reticulum kinase in tumor cell growth arrest and survival. Cancer Res (2008) 1.13
The cell biology of the unfolded protein response. Gastroenterology (2011) 1.11
Druggable sensors of the unfolded protein response. Nat Chem Biol (2014) 1.09
Identification of Toyocamycin, an agent cytotoxic for multiple myeloma cells, as a potent inhibitor of ER stress-induced XBP1 mRNA splicing. Blood Cancer J (2012) 1.09
Resveratrol triggers the pro-apoptotic endoplasmic reticulum stress response and represses pro-survival XBP1 signaling in human multiple myeloma cells. Exp Hematol (2011) 1.08
A novel mouse model for multiple myeloma (MOPC315.BM) that allows noninvasive spatiotemporal detection of osteolytic disease. PLoS One (2012) 1.07
Genetic variation of promoter sequence modulates XBP1 expression and genetic risk for vitiligo. PLoS Genet (2009) 1.07
Inherited genetic susceptibility to multiple myeloma. Leukemia (2013) 1.04
Pathogenesis beyond the cancer clone(s) in multiple myeloma. Blood (2015) 1.04
(18)F-FDG-PET/CT imaging in an IL-6- and MYC-driven mouse model of human multiple myeloma affords objective evaluation of plasma cell tumor progression and therapeutic response to the proteasome inhibitor ixazomib. Blood Cancer J (2013) 1.03
A CreER-based random induction strategy for modeling translocation-associated sarcomas in mice. Cancer Res (2009) 1.03
Molecular chaperone gp96 is a novel therapeutic target of multiple myeloma. Clin Cancer Res (2013) 1.03
Notch signaling expands a pre-malignant pool of T-cell acute lymphoblastic leukemia clones without affecting leukemia-propagating cell frequency. Leukemia (2012) 1.03
Transcription factor MIST1 in terminal differentiation of mouse and human plasma cells. Physiol Genomics (2010) 1.02
ER stress affects processing of MHC class I-associated peptides. BMC Immunol (2009) 1.02
Overexpression of TCL1 activates the endoplasmic reticulum stress response: a novel mechanism of leukemic progression in mice. Blood (2012) 1.00
Potential for therapeutic manipulation of the UPR in disease. Semin Immunopathol (2013) 0.99
Phosphoregulation of Ire1 RNase splicing activity. Nat Commun (2014) 0.97
Endoplasmic reticulum stress is chronically activated in chronic pancreatitis. J Biol Chem (2014) 0.97
Inflammation and cellular stress: a mechanistic link between immune-mediated and metabolically driven pathologies. Eur J Nutr (2011) 0.97
Mouse models as a translational platform for the development of new therapeutic agents in multiple myeloma. Curr Cancer Drug Targets (2012) 0.97
Expression of XBP1s in bone marrow stromal cells is critical for myeloma cell growth and osteoclast formation. Blood (2012) 0.97
Hepatitis C virus and cellular stress response: implications to molecular pathogenesis of liver diseases. Viruses (2012) 0.97
Splicing factor SRSF3 is crucial for hepatocyte differentiation and metabolic function. Nat Commun (2013) 0.96
The genetic architecture of multiple myeloma. Adv Hematol (2014) 0.96
Perforin-mediated suppression of B-cell lymphoma. Proc Natl Acad Sci U S A (2009) 0.94
Genome-wide profiling of histone H3 lysine 27 and lysine 4 trimethylation in multiple myeloma reveals the importance of Polycomb gene targeting and highlights EZH2 as a potential therapeutic target. Oncotarget (2016) 0.94
Dinaciclib (SCH727965) inhibits the unfolded protein response through a CDK1- and 5-dependent mechanism. Mol Cancer Ther (2013) 0.94
Mndal, a new interferon-inducible family member, is highly polymorphic, suppresses cell growth, and may modify plasmacytoma susceptibility. Blood (2009) 0.93
Expression pattern of XBP1(S) in human B-cell lymphomas. Haematologica (2009) 0.93
Characterization of a novel mouse model of multiple myeloma and its use in preclinical therapeutic assessment. PLoS One (2013) 0.91
Novel therapeutic strategies for multiple myeloma. Exp Hematol (2015) 0.91
Understanding the hypoxic niche of multiple myeloma: therapeutic implications and contributions of mouse models. Dis Model Mech (2012) 0.90
Animal models: Towards a myeloma mouse. Nature (2011) 0.89
The role of endoplasmic reticulum stress in maintaining and targeting multiple myeloma: a double-edged sword of adaptation and apoptosis. Front Genet (2013) 0.89
Cancer Microenvironment and Endoplasmic Reticulum Stress Response. Mediators Inflamm (2015) 0.88
Targeting the IRE1α-XBP1 branch of the unfolded protein response in human diseases. Semin Cancer Biol (2015) 0.88
Bone marrow microenvironment in myelomagenesis: its potential role in early diagnosis. Expert Rev Mol Diagn (2010) 0.87
Transgenic expression of entire hepatitis B virus in mice induces hepatocarcinogenesis independent of chronic liver injury. PLoS One (2011) 0.87
Preclinical studies of novel targeted therapies. Hematol Oncol Clin North Am (2007) 0.86
GP130 activation induces myeloma and collaborates with MYC. J Clin Invest (2014) 0.86
Retracted XBP1S associates with RUNX2 and regulates chondrocyte hypertrophy. J Biol Chem (2012) 0.86
Multiple autophosphorylations significantly enhance the endoribonuclease activity of human inositol requiring enzyme 1α. BMC Biochem (2014) 0.85
The nuclear receptor peroxisome proliferator-activated receptor-β/δ (PPARβ/δ) promotes oncogene-induced cellular senescence through repression of endoplasmic reticulum stress. J Biol Chem (2014) 0.85
Tetraspanin-induced death of myeloma cell lines is autophagic and involves increased UPR signalling. Br J Cancer (2009) 0.84
Endoplasmic reticulum quality control in cancer: Friend or foe. Semin Cancer Biol (2015) 0.83
XBP1S protects cells from ER stress-induced apoptosis through Erk1/2 signaling pathway involving CHOP. Histochem Cell Biol (2012) 0.83
Primary neoplasms of bones in mice: retrospective study and review of literature. Vet Pathol (2011) 0.83
NOD/SCID-GAMMA mice are an ideal strain to assess the efficacy of therapeutic agents used in the treatment of myeloma bone disease. PLoS One (2015) 0.82
Endoplasmic reticulum stress-independent activation of unfolded protein response kinases by a small molecule ATP-mimic. Elife (2015) 0.82
Therapeutic potential of targeting IRES-dependent c-myc translation in multiple myeloma cells during ER stress. Oncogene (2015) 0.82
Cell intrinsic and extrinsic activators of the unfolded protein response in cancer: Mechanisms and targets for therapy. Semin Cancer Biol (2015) 0.82
Expression and function of a novel isoform of Sox5 in malignant B cells. Leuk Res (2013) 0.81
Genetic targeting of the active transcription factor XBP1s to dendritic cells potentiates vaccine-induced prophylactic and therapeutic antitumor immunity. Mol Ther (2011) 0.81
Molecular mechanisms of human IRE1 activation through dimerization and ligand binding. Oncotarget (2015) 0.81
A novel rapid-onset high-penetrance plasmacytoma mouse model driven by deregulation of cMYC cooperating with KRAS12V in BALB/c mice. Blood Cancer J (2013) 0.81
Overexpression of X-Box Binding Protein 1 (XBP1) Correlates to Poor Prognosis and Up-Regulation of PI3K/mTOR in Human Osteosarcoma. Int J Mol Sci (2015) 0.80
Anti-apoptotic function of Xbp1 as an IL-3 signaling molecule in hematopoietic cells. Cell Death Dis (2011) 0.80
Enhancer alterations in cancer: a source for a cell identity crisis. Genome Med (2014) 0.80
High expression of endoplasmic reticulum chaperone grp94 is a novel molecular hallmark of malignant plasma cells in multiple myeloma. J Hematol Oncol (2015) 0.80
Significance analysis of microarrays applied to the ionizing radiation response. Proc Natl Acad Sci U S A (2001) 132.88
IRE1 couples endoplasmic reticulum load to secretory capacity by processing the XBP-1 mRNA. Nature (2002) 16.52
A network-based analysis of systemic inflammation in humans. Nature (2005) 12.60
Plasma cell differentiation requires the transcription factor XBP-1. Nature (2001) 9.72
Plasma cell differentiation and the unfolded protein response intersect at the transcription factor XBP-1. Nat Immunol (2003) 7.06
XBP1, downstream of Blimp-1, expands the secretory apparatus and other organelles, and increases protein synthesis in plasma cell differentiation. Immunity (2004) 6.72
High-resolution genomic profiles of human lung cancer. Proc Natl Acad Sci U S A (2005) 6.52
IRE1-mediated unconventional mRNA splicing and S2P-mediated ATF6 cleavage merge to regulate XBP1 in signaling the unfolded protein response. Genes Dev (2002) 6.37
Global gene expression profiling of multiple myeloma, monoclonal gammopathy of undetermined significance, and normal bone marrow plasma cells. Blood (2002) 5.47
Complementary signaling pathways regulate the unfolded protein response and are required for C. elegans development. Cell (2001) 5.39
Multiple myeloma: evolving genetic events and host interactions. Nat Rev Cancer (2002) 5.30
High-resolution genomic profiles define distinct clinico-pathogenetic subgroups of multiple myeloma patients. Cancer Cell (2006) 5.01
Proteasome inhibitors disrupt the unfolded protein response in myeloma cells. Proc Natl Acad Sci U S A (2003) 4.47
Molecular pathogenesis and a consequent classification of multiple myeloma. J Clin Oncol (2005) 3.93
The unfolding tale of the unfolded protein response. Cell (2001) 2.90
Expression of the immunoglobulin C mu gene in mouse T and B lymphoid and myeloid cell lines. Proc Natl Acad Sci U S A (1980) 2.57
Castleman's disease. Mayo Clin Proc (1995) 2.31
129-derived strains of mice are deficient in DNA polymerase iota and have normal immunoglobulin hypermutation. J Exp Med (2003) 2.26
Insights into the multistep transformation of MGUS to myeloma using microarray expression analysis. Blood (2003) 2.23
The X-box binding protein-1 transcription factor is required for plasma cell differentiation and the unfolded protein response. Immunol Rev (2003) 2.20
Expression of BCMA, TACI, and BAFF-R in multiple myeloma: a mechanism for growth and survival. Blood (2003) 2.12
Focus on multiple myeloma. Cancer Cell (2004) 2.10
Lymphoma B cells evade apoptosis through the TNF family members BAFF/BLyS and APRIL. J Immunol (2004) 2.01
Renal pathologic spectrum in an autopsy series of patients with plasma cell dyscrasia. Arch Pathol Lab Med (2004) 1.85
Insertion of c-Myc into Igh induces B-cell and plasma-cell neoplasms in mice. Cancer Res (2005) 1.83
Mcl-1 regulation and its role in multiple myeloma. Cell Cycle (2004) 1.68
Stop and go: anti-proliferative and mitogenic functions of the transcription factor C/EBPbeta. Cell Cycle (2006) 1.58
Identification of genes modulated in multiple myeloma using genetically identical twin samples. Blood (2003) 1.56
A murine model of human myeloma bone disease. Bone (1997) 1.53
Novel targeted deregulation of c-Myc cooperates with Bcl-X(L) to cause plasma cell neoplasms in mice. J Clin Invest (2004) 1.53
Transcriptional regulation of the human TLR9 gene. J Immunol (2004) 1.38
Stressed-out B cells? Plasma-cell differentiation and the unfolded protein response. Trends Immunol (2004) 1.31
Expression of the bcl-2 family of pro- and anti-apoptotic genes in multiple myeloma and normal plasma cells: regulation during interleukin-6(IL-6)-induced growth and survival. Eur J Haematol (2002) 1.28
Tula hantavirus triggers pro-apoptotic signals of ER stress in Vero E6 cells. Virology (2005) 1.27
Upregulation and overexpression of human X-box binding protein 1 (hXBP-1) gene in primary breast cancers. Breast Cancer (2003) 1.19
POEMS Syndrome. Hematology Am Soc Hematol Educ Program (2005) 1.18
Epidemiology and outcomes research for MGUS, myeloma and amyloidosis. Eur J Cancer (2006) 1.12
Identification of c-myc promoter-binding protein and X-box binding protein 1 as interleukin-6 target genes in human multiple myeloma cells. Int J Oncol (1999) 1.03
Systemic amyloidosis. Crit Rev Oncol Hematol (1990) 1.01
Opposing roles of C/EBPbeta and AP-1 in the control of fibroblast proliferation and growth arrest-specific gene expression. J Biol Chem (2003) 0.89
Somatic mutations affect key pathways in lung adenocarcinoma. Nature (2008) 30.02
International network of cancer genome projects. Nature (2010) 20.35
Initial genome sequencing and analysis of multiple myeloma. Nature (2011) 17.28
Malignant astrocytic glioma: genetics, biology, and paths to treatment. Genes Dev (2007) 17.20
A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med (2003) 16.11
Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med (2005) 15.30
BET bromodomain inhibition as a therapeutic strategy to target c-Myc. Cell (2011) 14.34
Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning. Nat Med (2002) 14.01
Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med (2008) 13.06
High-throughput oncogene mutation profiling in human cancer. Nat Genet (2007) 12.68
FoxOs are critical mediators of hematopoietic stem cell resistance to physiologic oxidative stress. Cell (2007) 12.33
The tumor suppressor LKB1 kinase directly activates AMP-activated kinase and regulates apoptosis in response to energy stress. Proc Natl Acad Sci U S A (2004) 12.30
Molecular profiling of diffuse large B-cell lymphoma identifies robust subtypes including one characterized by host inflammatory response. Blood (2004) 11.07
Coactivation of receptor tyrosine kinases affects the response of tumor cells to targeted therapies. Science (2007) 10.60
Somatic mutations of the histone H3K27 demethylase gene UTX in human cancer. Nat Genet (2009) 10.21
Hepatocellular carcinoma pathogenesis: from genes to environment. Nat Rev Cancer (2006) 10.05
Stem-cell ageing modified by the cyclin-dependent kinase inhibitor p16INK4a. Nature (2006) 9.20
FoxOs are lineage-restricted redundant tumor suppressors and regulate endothelial cell homeostasis. Cell (2007) 8.94
Activated Kras and Ink4a/Arf deficiency cooperate to produce metastatic pancreatic ductal adenocarcinoma. Genes Dev (2003) 8.27
Endogenous oncogenic K-ras(G12D) stimulates proliferation and widespread neoplastic and developmental defects. Cancer Cell (2004) 8.16
Braf(V600E) cooperates with Pten loss to induce metastatic melanoma. Nat Genet (2009) 7.81
Melanoma genome sequencing reveals frequent PREX2 mutations. Nature (2012) 7.77
The LKB1 tumor suppressor negatively regulates mTOR signaling. Cancer Cell (2004) 7.77
Pancreatic cancer biology and genetics. Nat Rev Cancer (2002) 7.36
Oncogenic Kras maintains pancreatic tumors through regulation of anabolic glucose metabolism. Cell (2012) 7.36
HDAC2 negatively regulates memory formation and synaptic plasticity. Nature (2009) 6.96
Cytokinesis failure generating tetraploids promotes tumorigenesis in p53-null cells. Nature (2005) 6.86
Glutamine supports pancreatic cancer growth through a KRAS-regulated metabolic pathway. Nature (2013) 6.53
High-resolution genomic profiles of human lung cancer. Proc Natl Acad Sci U S A (2005) 6.52
Telomere dysfunction induces metabolic and mitochondrial compromise. Nature (2011) 6.36
Lenalidomide after stem-cell transplantation for multiple myeloma. N Engl J Med (2012) 6.24
Pancreatic cancers require autophagy for tumor growth. Genes Dev (2011) 6.17
Loss of the Lkb1 tumour suppressor provokes intestinal polyposis but resistance to transformation. Nature (2002) 6.10
How stem cells age and why this makes us grow old. Nat Rev Mol Cell Biol (2007) 5.80
Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas. N Engl J Med (2015) 5.71
Chromosomally unstable mouse tumours have genomic alterations similar to diverse human cancers. Nature (2007) 5.65
Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets. Nat Rev Cancer (2007) 5.57
Smad4 is dispensable for normal pancreas development yet critical in progression and tumor biology of pancreas cancer. Genes Dev (2006) 5.53
Small molecule RITA binds to p53, blocks p53-HDM-2 interaction and activates p53 function in tumors. Nat Med (2004) 5.48
The iron exporter ferroportin/Slc40a1 is essential for iron homeostasis. Cell Metab (2005) 5.32
DNA breaks and chromosome pulverization from errors in mitosis. Nature (2012) 5.19
Epidermal growth factor receptor and Ink4a/Arf: convergent mechanisms governing terminal differentiation and transformation along the neural stem cell to astrocyte axis. Cancer Cell (2002) 5.11
Insulin signaling in osteoblasts integrates bone remodeling and energy metabolism. Cell (2010) 5.08
High-resolution genomic profiles define distinct clinico-pathogenetic subgroups of multiple myeloma patients. Cancer Cell (2006) 5.01
Regulation of the TSC pathway by LKB1: evidence of a molecular link between tuberous sclerosis complex and Peutz-Jeghers syndrome. Genes Dev (2004) 5.00
p53 and Pten control neural and glioma stem/progenitor cell renewal and differentiation. Nature (2008) 5.00
NF-kappa B as a therapeutic target in multiple myeloma. J Biol Chem (2002) 4.94
Marked genomic differences characterize primary and secondary glioblastoma subtypes and identify two distinct molecular and clinical secondary glioblastoma entities. Cancer Res (2006) 4.80
Feedback circuit among INK4 tumor suppressors constrains human glioblastoma development. Cancer Cell (2008) 4.71
Connecting chromosomes, crisis, and cancer. Science (2002) 4.69
Multiple myeloma. Lancet (2009) 4.60
SMAD4-dependent barrier constrains prostate cancer growth and metastatic progression. Nature (2011) 4.57
Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma. Blood (2002) 4.56
Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma. Blood (2010) 4.52
Proteasome inhibitors disrupt the unfolded protein response in myeloma cells. Proc Natl Acad Sci U S A (2003) 4.47
Pretreatment mitochondrial priming correlates with clinical response to cytotoxic chemotherapy. Science (2011) 4.46
PI3 kinase signals BCR-dependent mature B cell survival. Cell (2009) 4.43
Lenalidomide causes selective degradation of IKZF1 and IKZF3 in multiple myeloma cells. Science (2013) 4.39
Telomerase reactivation reverses tissue degeneration in aged telomerase-deficient mice. Nature (2010) 4.36
Molecular sequelae of proteasome inhibition in human multiple myeloma cells. Proc Natl Acad Sci U S A (2002) 4.33
Suppression of ovarian follicle activation in mice by the transcription factor Foxo3a. Science (2003) 4.32
Foxo1 links homing and survival of naive T cells by regulating L-selectin, CCR7 and interleukin 7 receptor. Nat Immunol (2009) 4.31
Telomeres and telomerase in cancer. Carcinogenesis (2009) 4.28
MYD88 L265P somatic mutation in Waldenström's macroglobulinemia. N Engl J Med (2012) 4.26
Advances in biology of multiple myeloma: clinical applications. Blood (2004) 4.13
Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1. Blood (2011) 4.00
Tumor cell-specific bioluminescence platform to identify stroma-induced changes to anticancer drug activity. Nat Med (2010) 4.00
A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma. Blood (2006) 3.89
Small-molecule inhibition of proteasome and aggresome function induces synergistic antitumor activity in multiple myeloma. Proc Natl Acad Sci U S A (2005) 3.86
Identification of new diamine scaffolds with activity against Mycobacterium tuberculosis. J Med Chem (2006) 3.75
High-resolution characterization of the pancreatic adenocarcinoma genome. Proc Natl Acad Sci U S A (2004) 3.75
The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications. Blood (2002) 3.73
SCF(FBW7) regulates cellular apoptosis by targeting MCL1 for ubiquitylation and destruction. Nature (2011) 3.69
Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trial. Blood (2007) 3.66
Involvement of Foxo transcription factors in angiogenesis and postnatal neovascularization. J Clin Invest (2005) 3.66
Molecular mechanisms mediating antimyeloma activity of proteasome inhibitor PS-341. Blood (2002) 3.62
IL-7 engages multiple mechanisms to overcome chronic viral infection and limit organ pathology. Cell (2011) 3.61
Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib. J Clin Oncol (2006) 3.60
Zinc finger nucleases: custom-designed molecular scissors for genome engineering of plant and mammalian cells. Nucleic Acids Res (2005) 3.47
Proteasome inhibition as a novel therapeutic target in human cancer. J Clin Oncol (2005) 3.43